Plenary 03: Innovation in HIV Vaccine Discovery

Thursday, 10 October | 08:30 – 10:00

Maria Jose Alonso

PL03.01 | 08:30 – 09:00
Nanotechnology Approaches for Designing Novel HIV Vaccines

Maria Jose Alonso
University of Santiago de Compostela, Spain

 

Biography

María José Alonso is full professor of Biopharmaceutics and Pharmaceutical Technology at the University of Santiago de Compostela (USC). She served as Vice-Rector of Research and Innovation of the USC (2006-2010). Alonso has made pioneering contributions in the area of polymer nanocarriers for macromolecular vaccine/drug delivery. She has been responsible of 46 research projects and contracts, 7 of which have been large cooperative project financed by the WHO, the “Bill ad Melinda Gates Foundation” and the European Commission. She has actively collaborated with industry through research contracts and the licence of patents (inventor in 16 patents). She is the author of more than 200 international scientific articles and book chapters with more than 8000 cites (H factor 53; TOP TEN in Pharmacology -Times Higher Education international ranking). Alonso is a member of The Royal National Academy of Pharmacy. She is part of the scientific board of a number of societies, among them the Controlled Release Society. She has also received several of Awards, among them the “King Jaume I Award”.

 

 
Béhazine Combadiere 

PL03.02 | 09:00 – 09:30
Cutaneous Routes for HIV Vaccination Strategies

Béhazine Combadiere
INSERM, UPMC, France

Biography

Béhazine Combadiere has been pioneer in vaccine immunity and delivery by hair follicular targeting of biomolecules and vaccine. She has brought from concept into clinical trials this novel needle-free vaccination method. Under the European contract, she coordinates the EU-FP7 project CUT’HIVAC for Cutaneous and Mucosal HIV vaccination (January 2010- December 2014). CUT’HIVAC is a large consortium of 14 European and ICPC (Mozambic and Peru) involved in the development of cutaneous and mucosal vaccination strategies against HIV. During the PhD program, Behazine Combadiere contributed to the field of HIV immune responses by studying negative regulation of HIV-specific CD8 responses in HIV-infected individuals. She completed her immunological knowledge and expertise in murine models at the Laboratory of Immunology at the National Institutes of Health (NIH, Bethesda, MD, USA)in laboratories of Drs Michael Lenardo and Ronald J Germain with whom she co-published several manuscripts in top 1-10% journal. Back to France in 1998, she obtained a permanent position as a research associate and young investigator award (French Agency of research) and pursues her research to decipher immune responses to infectious diseases (influenza, HIV and Smallpox).

 

 
Adrian Hill

PL03.03 | 11:20 – 11:45
HIV Vaccine Development: A View from the Outside

Adrian Hill
Jenner Institute, University of Oxford, United Kingdom

Biography

Adrian Hill trained at Trinity College Dublin and Oxford and is now Professor of Human Genetics and Director of the Jenner Institute at Oxford University, which one of the largest non-profit vaccine institutes.  He also leads a research programme on genetic susceptibility to major infectious diseases. He is best known for developing promising new vaccine candidates against malaria. His group discovered the ability of heterologous prime-boost immunisation to induce potent T cell responses pre-clinically and has developed this approach to phase IIb clinical trials in Africa. He has also pioneered the use of small rapid clinical trials to provide initial safety and immunogenicity with a range of novel vaccine concepts. The Jenner Institute aims to accelerate public sector vaccine development for infectious diseases and links human and veterinary vaccine development. Jenner Institute scientists are developing leading new vaccine candidates against malaria, HIV, tuberculosis and pandemic influenza.